NCT05572970 2025-04-30Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)Agenus Inc.Available
NCT04156100 2022-03-03A Study in Subjects With Advanced Solid TumorsAgenus Inc.Phase 1 Terminated19 enrolled